Healthcare Industry News: Insmed
News Release - July 28, 2008
Jim Miller, Ph.D. Joins Insmed Therapeutic Proteins as Vice President of Process DevelopmentDr. Miller's Work Will Concentrate on the Continued Development of Insmed's Follow-On Biologics Product Portfolio
RICHMOND, Va., July 28 (HSMN NewsFeed) -- Insmed Inc. (Nasdaq: INSM ), a developer of follow-on biologics and biopharmaceuticals, today announced that Jim Miller, Ph.D. has joined Insmed's management team as Vice President of Process Development. Dr. Miller will play an important role in the development of Insmed Therapeutic Proteins' emerging portfolio of follow-on biologics.
Dr. Miller, 56, brings over 25 years of experience in biopharmaceutical product research and preclinical development to his new position. Prior to joining Insmed, he served as Executive Vice President of Product Development at Saronyx, Inc., a private life sciences company that he also co-founded. Dr. Miller earlier held senior development, operations and research positions at both Reneneron Pharmaceuticals, Inc., and Amgen. His strategic and management expertise, which center around the biopharmaceutical development process, includes team management, research design and implementation, strategic planning, product development, and product marketing.
Dr. Miller received his Ph.D. in Chemistry from the California Institute of Technology and performed his Postdoctoral work at Yale University School of Medicine. He has been published on numerous occasions in well-respected scientific periodicals, including The Journal of Neuroscience, The Archive of Biochemistry and Biophysics and The Journal of Molecular Biology.
Doug Farrar, Senior Vice President, Manufacturing Operations for Insmed commented, "We are excited to have Jim join our experienced team. His background is well suited to further accelerate progress on our follow-on biologics portfolio as we reach a critical stage in the development process of these product candidates."
Dr. Miller commented, "I am pleased to be joining the Insmed team, which has consistently demonstrated its advanced knowledge of biologics development, manufacturing capability and its skilled scientific and technical workforce. I am excited to be a part of the first U.S.-based biotechnology company to develop a comprehensive portfolio of follow-on biologics and look forward to working with the team to continue advancing these product candidates as rapidly as possible through the development process."
Insmed Inc. is a biopharmaceutical company with unique protein process development and manufacturing experience and a proprietary protein platform aimed at niche markets with unmet medical needs. For more information, please visit www.Insmed.com.
This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, strategic alternatives, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that strategic alternatives may never be consummated, product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of product candidates, the FDA may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our entrance into the follow-on biologics market may be unsuccessful, our common stock could be delisted from The NASDAQ Capital Market and other risks and challenges detailed in the Company's filings with the U.S. Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for the year ended December 31, 2007. Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.